Clinical Trials in Paramus, New Jersey
1 recruiting
Showing 1–15 of 15 trials
Recruiting
Phase 3
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Stage IIIB Lung Cancer AJCC v8Stage IV Lung Cancer AJCC v8Advanced Lung Non-Squamous Non-Small Cell Carcinoma+2 more
National Cancer Institute (NCI)300 enrolled604 locationsNCT04181060
Recruiting
Phase 2Phase 3
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
Non-small Cell Lung Cancer
BioNTech SE1,260 enrolled184 locationsNCT06712316
Recruiting
Phase 3
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Stage IIIA Lung Cancer AJCC v8Stage IIIB Lung Cancer AJCC v8Lung Non-Small Cell Carcinoma+3 more
National Cancer Institute (NCI)1,210 enrolled1149 locationsNCT04267848
Recruiting
Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients
PrECOG, LLC.538 enrolled144 locationsNCT06538038
Recruiting
Phase 2
A Study of V940/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)
Merck Sharp & Dohme LLC180 enrolled21 locationsNCT07221474
Recruiting
Phase 3
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Eli Lilly and Company1,264 enrolled424 locationsNCT06119581
Recruiting
Phase 3
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage I Breast Cancer AJCC v8+1 more
Alliance for Clinical Trials in Oncology1,295 enrolled829 locationsNCT05812807
Recruiting
Phase 3
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Breast Cancer
NRG Oncology3,960 enrolled1209 locationsNCT05879926
Recruiting
Phase 3
E-Mindfulness Approaches for Living After Breast Cancer
Breast CancerDepression
NRG Oncology402 enrolled277 locationsNCT06748222
Recruiting
Phase 3
Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer
Stage IIIA Lung Cancer AJCC v8Stage IIIB Lung Cancer AJCC v8Resectable Lung Non-Small Cell Carcinoma+1 more
Alliance for Clinical Trials in Oncology1,100 enrolled370 locationsNCT06632327
Recruiting
Phase 3
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
Carcinoma, Non-Small Cell Lung
AstraZeneca830 enrolled288 locationsNCT06868277
Recruiting
Phase 1Phase 2
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
Carcinoma, Non-Small Cell Lung
Genprex, Inc.158 enrolled10 locationsNCT04486833
Recruiting
Phase 3
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast CarcinomaMetastatic Lung Non-Small Cell Carcinoma+7 more
NRG Oncology269 enrolled242 locationsNCT06500455
Recruiting
Phase 2
Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study
Stage IVB Prostate Cancer AJCC v8Prostate AdenocarcinomaOligometastatic Prostate Carcinoma+2 more
NRG Oncology194 enrolled239 locationsNCT05053152
Recruiting
Phase 3
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
Metastatic Non Small Cell Lung Cancer
Daiichi Sankyo740 enrolled243 locationsNCT05215340